Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
33%(2 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_4
4
44%
Ph phase_2
2
22%
Ph not_applicable
1
11%

Phase Distribution

0

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
2(28.6%)
Phase 4Post-market surveillance
4(57.1%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(6)
Terminated(2)
Other(1)

Detailed Status

Completed6
unknown1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (28.6%)
Phase 44 (57.1%)
N/A1 (14.3%)

Trials by Status

unknown111%
terminated111%
completed667%
withdrawn111%

Recent Activity

0 active trials
Showing 5 of 9
completed

Special Drug Use Surveillance of Entresto Tablets (Hypertension)

NCT05976230
completedphase_2

Role of ARNi in Ventricular Remodeling in Hypertensive LVH

NCT03553810
completed

Special Drug Use Surveillance for Entresto Tablets

NCT04781881
withdrawnphase_4

Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD

NCT03279861
completedphase_4

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

NCT03893526
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05976230

Special Drug Use Surveillance of Entresto Tablets (Hypertension)

Completed
NCT03553810Phase 2

Role of ARNi in Ventricular Remodeling in Hypertensive LVH

Completed
NCT04781881

Special Drug Use Surveillance for Entresto Tablets

Completed
NCT03279861Phase 4

Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD

Withdrawn
NCT03893526Phase 4

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

Completed
NCT02754518Phase 4

Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis

Completed
NCT02636283Phase 2

Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease

Terminated
NCT03821701Not Applicable

Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure

Unknown
NCT03717688Phase 4

The Effects of Neprilysin on Glucagon-like Peptide-1

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9